Some links on this site are affiliate links. If you purchase through them, we may earn a small commission at no extra cost to you. We only recommend products we believe in.
The gap between the 2018 law change and what NHS patients can actually access is bigger than most men realise. I've spoken to friends with genuine treatment-resistant pain who only found a route through a regulated private clinic, not because they wanted to, but because the NHS door was closed.
The 2018 legalisation of medical cannabis in the UK was announced with significant fanfare. In practice, NHS access has remained extremely limited - to the frustration of many patients with conditions the evidence supports treating with cannabis.
Here's an honest explanation of why NHS medical cannabis access is so restricted and what the legitimate private pathway looks like for men who qualify.
The 2018 Rescheduling: What It Actually Changed
In November 2018, cannabis-based medicinal products (CBMPs) were moved from Schedule 1 (no accepted medical use) to Schedule 2 (accepted medical use, can be prescribed) of the Misuse of Drugs Regulations.
This change meant that specialist doctors could legally prescribe CBMPs. It did not mandate NHS coverage. It did not require NICE guidance to endorse specific products. It created a legal framework without creating an NHS pathway.
Why NHS Access Remains Limited
NICE has issued restrictive guidance. The National Institute for Health and Care Excellence reviewed medical cannabis and in 2019 recommended NHS prescribing only for three specific conditions: childhood-onset epilepsy (Dravet syndrome, Lennox-Gastaut syndrome), nausea and vomiting from chemotherapy, and spasticity from multiple sclerosis (Sativex). Chronic pain - the most common indication in private medical cannabis clinics - was not included due to NICE's assessment that the evidence was insufficient for NHS commissioning.
GP prescribing remains effectively blocked. NICE guidance means GPs cannot initiate medical cannabis prescriptions for conditions beyond the three above. They can refer to specialists, but specialist NHS medical cannabis prescribing is extremely limited geographically.
NHS specialist pathways are inconsistent. Where specialist NHS prescribers exist (primarily in neurology and specialist pain services in some trusts), waiting times are long and clinical criteria restrictive.
Cost pressures. Medical cannabis products are expensive compared to generic alternatives. NHS commissioners have limited appetite to fund treatments without NICE endorsement.
The Practical Result
A man with chronic neuropathic pain that hasn't responded to gabapentin, amitriptyline, or specialist pain management - a patient who would typically qualify for medical cannabis at a private clinic - has essentially no NHS route to this treatment. His options in the NHS are continuing to try conventional analgesics or opioid therapy, which carry their own significant side effect profiles.
This situation is likely to change as more human trial evidence accumulates and NICE re-evaluates. But for men who need treatment now, the NHS isn't the pathway.
The Private Clinic Route
The private medical cannabis clinic ecosystem has grown to fill this gap. There are now several regulated UK clinics - operating entirely within the 2018 legal framework - that provide:
- Specialist medical assessment by GMC-registered consultants
- Evidence-based prescribing for appropriate conditions
- MHRA-regulated products dispensed through registered pharmacies
- Ongoing monitoring and dose optimisation
Releaf is one of the more established names in this space. The process is fully online from eligibility check through to product delivery, with video consultations with specialist doctors.
Who qualifies: Diagnosed chronic condition (typically chronic pain, anxiety disorder, PTSD, or MS-related symptoms) that hasn't responded adequately to conventional treatment. The clinic assesses eligibility - there's no cost until after the initial eligibility screen confirms you're likely to qualify.
Cost: Initial consultation approximately £99–149. Monthly ongoing costs for medication and monitoring typically £150–300 depending on products and dose. These are private costs with no NHS reimbursement.
Is the Private Route Worth It?
For men with genuine treatment-resistant chronic conditions - particularly pain that hasn't responded to conventional approaches - the cost needs to be weighed against:
- The ongoing cost of other treatments that aren't working
- The cost of conditions like poor sleep, reduced work capacity, and quality of life on chronic unmanaged pain
- The alternative of purchasing cannabis illegally (which carries legal risk, unknown product quality, and no clinical monitoring)
For men who genuinely qualify, the private route is both legal and clinically legitimate. The key is choosing a regulated clinic with proper specialist assessment rather than one that functions as a rubber stamp.
NHS medical cannabis access is essentially limited to three conditions, none of which is chronic pain. For most UK men with treatment-resistant conditions that fit the evidence base, a regulated private specialist clinic is currently the only legal route.
Check your eligibility with Releaf →
Medical cannabis is a prescription-only medicine in the UK available through specialist prescribers. This article is for educational purposes and does not constitute medical advice.
